Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F22%3A00569226" target="_blank" >RIV/60077344:_____/22:00569226 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?pes=vor" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?pes=vor</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/bs.armc.2022.08.003" target="_blank" >10.1016/bs.armc.2022.08.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals

Popis výsledku v původním jazyce

Tick-borne encephalitis (TBE) is one of the most serious neurological infections in Europe and Northeastern Asia. The causative agent of TBE is the tick-borne encephalitis virus (TBEV). Although several effective vaccines are legislated to prevent TBE, there are currently no approved treatments/anti-TBEV drugs other than supportive measures. Therefore, there is an urgent medical need for the development of novel, specific, and effective antivirals to treat patients with TBEV infection. This report summarizes the available information on antiviral research on small molecule-based inhibitors of TBEV replication. The main focus is on the description of nucleoside analogs, a leading group of antiviral compounds with the highest anti-TBEV potency. Various sugar/nucleobase modifications of the nucleoside scaffold that have been made to maximize the antiviral activity and decrease the cytotoxicity of the compounds are discussed. Emphasis is also placed on elucidating the mechanism of action of the inhibitors studied and their relationship to the development of antiviral resistance. Moreover, a brief overview of nonnucleoside inhibitors, natural compounds, repurposed drugs, and synthetic broad-spectrum antivirals is also part of this chapter. The review shows that specific therapies based on small-molecule inhibitors, in combination with effective vaccination strategies, could be effective prophylactic and curative tools to control TBEV infections in humans.

Název v anglickém jazyce

Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals

Popis výsledku anglicky

Tick-borne encephalitis (TBE) is one of the most serious neurological infections in Europe and Northeastern Asia. The causative agent of TBE is the tick-borne encephalitis virus (TBEV). Although several effective vaccines are legislated to prevent TBE, there are currently no approved treatments/anti-TBEV drugs other than supportive measures. Therefore, there is an urgent medical need for the development of novel, specific, and effective antivirals to treat patients with TBEV infection. This report summarizes the available information on antiviral research on small molecule-based inhibitors of TBEV replication. The main focus is on the description of nucleoside analogs, a leading group of antiviral compounds with the highest anti-TBEV potency. Various sugar/nucleobase modifications of the nucleoside scaffold that have been made to maximize the antiviral activity and decrease the cytotoxicity of the compounds are discussed. Emphasis is also placed on elucidating the mechanism of action of the inhibitors studied and their relationship to the development of antiviral resistance. Moreover, a brief overview of nonnucleoside inhibitors, natural compounds, repurposed drugs, and synthetic broad-spectrum antivirals is also part of this chapter. The review shows that specific therapies based on small-molecule inhibitors, in combination with effective vaccination strategies, could be effective prophylactic and curative tools to control TBEV infections in humans.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

10606 - Microbiology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Annual Reports in Medicinal Chemistry

ISBN

9780323988933

Počet stran výsledku

38

Strana od-do

"Roč. 58 (2022)"

Počet stran knihy

256

Název nakladatele

Springer

Místo vydání

Cham

Kód UT WoS kapitoly

—